BSE: 524075 | NSE: ALBERTDAVD | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Albert David Ltd is a good quality company.
The key valuation ratios of Albert David Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Albert David Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 18.2% | 46.5% | 14.3% | 7.9% | 20.6% | 13.7% | 12% | 18.1% | 17.1% | 27.8% | - |
| Value Creation Index ⓘ | 0.3 | 2.3 | 0.0 | -0.4 | 0.5 | 0.0 | -0.1 | 0.3 | 0.2 | 1.0 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 322 | 323 | 295 | 290 | 317 | 321 | 247 | 314 | 342 | 362 | 365 |
| Sales YoY Gr. | - | 0.3% | -8.5% | -1.7% | 9.3% | 1.1% | -22.9% | 26.7% | 9% | 6.1% | - |
| Adj EPS ⓘ | 23 | 33.3 | 23.7 | 11.4 | 26 | 36.4 | 37 | 57.1 | 62.9 | 130.3 | 120.1 |
| YoY Gr. | - | 44.5% | -28.8% | -52% | 128.7% | 39.8% | 1.6% | 54.4% | 10.1% | 107.2% | - |
| BVPS (₹) ⓘ | 162.6 | 239.8 | 320.7 | 325.8 | 368.7 | 390.4 | 428.2 | 489.7 | 545.9 | 671.1 | 724.1 |
| Adj Net Profit ⓘ | 13.2 | 19 | 13.5 | 6.5 | 14.9 | 20.8 | 21.1 | 32.6 | 35.9 | 74.3 | 69 |
| Cash Flow from Ops. ⓘ | 27.8 | 68 | 19.9 | 30 | 31.9 | 30.3 | 36.6 | 40.4 | 10.5 | 45.5 | - |
| Debt/CF from Ops. ⓘ | 1.1 | 0.3 | 1.5 | 0.9 | 0 | 0.1 | 0 | 0.1 | 0.5 | 0.1 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 1.3% | 2.7% | 13.6% | 6.1% | ||||
| Adj EPS ⓘ | 21.2% | 38% | 52.2% | 107.2% | ||||
| BVPSⓘ | 17.1% | 12.7% | 16.2% | 22.9% | ||||
| Share Price | 18.3% | 26.2% | 28.9% | 35.4% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 14.4 | 16.6 | 8.5 | 3.5 | 7.5 | 9.6 | 9 | 12.4 | 12.1 | 21.4 | 17.2 |
| Op. Profit Mgn % ⓘ | 11.5 | 9.7 | 6.6 | 5.9 | 9.4 | 10.6 | 7.8 | 13.1 | 13.2 | 13 | 6.9 |
| Net Profit Mgn % ⓘ | 4.1 | 5.9 | 4.6 | 2.2 | 4.7 | 6.5 | 8.5 | 10.4 | 10.5 | 20.5 | 18.8 |
| Debt to Equity ⓘ | 0.3 | 0.2 | 0.2 | 0.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Working Cap Days ⓘ | 174 | 161 | 194 | 212 | 193 | 190 | 227 | 183 | 201 | 201 | 189 |
| Cash Conv. Cycle ⓘ | 60 | 62 | 62 | 47 | 32 | 28 | 36 | 27 | 32 | 31 | 141 |
Return on Equity has increased versus last 3 years average to 17.20%
Sales growth is growing at healthy rate in last 3 years 13.57%
Net Profit is growing at healthy rate in last 3 years 52.16%
Sales growth is not so good in last 4 quarters at 7.65%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 120.1 | - |
| TTM Sales (₹ Cr.) | 365 | - |
| BVPS (₹.) ⓘ | 724.1 | - |
| Reserves (₹ Cr.) ⓘ | 408 | - |
| P/BV ⓘ | 1.79 | - |
| PE ⓘ | 10.79 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 912.10 / 1752.95 |
| All Time Low / High (₹) | 3.15 / 1752.95 |
| Market Cap (₹ Cr.) | 739 |
| Equity (₹ Cr.) | 5.7 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 43 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 322 | 323 | 295 | 290 | 317 | 321 | 247 | 314 | 342 | 362 |
| Operating Expenses ⓘ | 285 | 291 | 277 | 275 | 288 | 290 | 228 | 273 | 297 | 315 |
| Manufacturing Costs | 76 | 66 | 54 | 56 | 55 | 54 | 33 | 50 | 65 | 62 |
| Material Costs | 64 | 60 | 56 | 60 | 75 | 74 | 70 | 87 | 87 | 91 |
| Employee Cost | 75 | 82 | 83 | 86 | 90 | 90 | 83 | 85 | 81 | 88 |
| Other Costs ⓘ | 69 | 84 | 84 | 73 | 68 | 72 | 43 | 50 | 64 | 74 |
| Operating Profit ⓘ | 37 | 31 | 18 | 16 | 29 | 31 | 19 | 41 | 44 | 47 |
| Operating Profit Margin (%) | 11.5% | 9.7% | 6.1% | 5.4% | 9.2% | 9.5% | 7.8% | 13.1% | 13.0% | 13.0% |
| Other Income ⓘ | 2 | 2 | 16 | 10 | 21 | 7 | 17 | 16 | 15 | 58 |
| Interest ⓘ | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Depreciation ⓘ | 15 | 9 | 8 | 8 | 7 | 8 | 8 | 9 | 9 | 7 |
| Exceptional Items ⓘ | 0 | 41 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 20 | 63 | 26 | 16 | 43 | 29 | 27 | 47 | 51 | 97 |
| Tax ⓘ | 7 | 15 | 10 | 6 | 16 | 10 | 5 | 12 | 15 | 22 |
| Profit After Tax | 14 | 48 | 16 | 10 | 27 | 19 | 22 | 35 | 36 | 75 |
| PAT Margin (%) | 4.3% | 14.9% | 5.4% | 3.4% | 8.4% | 6.0% | 8.9% | 11.2% | 10.6% | 20.8% |
| Adjusted EPS (₹) | 24.0 | 84.1 | 28.0 | 17.2 | 46.7 | 33.6 | 38.8 | 61.8 | 63.4 | 132.2 |
| Dividend Payout Ratio (%) | 23% | 7% | 20% | 32% | 13% | 21% | 15% | 15% | 14% | 9% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 93 | 137 | 183 | 186 | 210 | 223 | 244 | 279 | 312 | 383 |
| Share Capital ⓘ | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves ⓘ | 87 | 131 | 177 | 180 | 205 | 217 | 239 | 274 | 306 | 377 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 28 | 20 | 30 | 28 | 0 | 1 | 1 | 4 | 4 | 2 |
| Long Term Debt | 6 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Short Term Debt | 22 | 20 | 30 | 28 | 0 | 0 | 0 | 4 | 4 | 2 |
| Trade Payables | 31 | 27 | 27 | 32 | 30 | 38 | 25 | 30 | 32 | 34 |
| Others Liabilities ⓘ | 80 | 81 | 110 | 116 | 135 | 136 | 135 | 161 | 165 | 185 |
| Total Liabilities ⓘ | 231 | 265 | 351 | 361 | 376 | 398 | 405 | 475 | 512 | 604 |
Fixed Assets | ||||||||||
| Gross Block | 168 | 172 | 221 | 192 | 192 | 212 | 212 | 223 | 222 | 231 |
| Accumulated Depreciation | 118 | 127 | 134 | 109 | 115 | 121 | 128 | 135 | 142 | 148 |
| Net Fixed Assetsⓘ | 49 | 44 | 87 | 83 | 77 | 91 | 84 | 88 | 80 | 83 |
| CWIP ⓘ | 5 | 5 | 9 | 5 | 5 | 2 | 1 | 1 | 3 | 7 |
| Investmentsⓘ | 17 | 48 | 59 | 68 | 113 | 122 | 138 | 183 | 193 | 273 |
| Inventories | 52 | 49 | 51 | 43 | 44 | 43 | 36 | 39 | 51 | 44 |
| Trade Receivables | 41 | 35 | 33 | 27 | 22 | 30 | 19 | 25 | 30 | 29 |
| Cash Equivalents | 10 | 23 | 15 | 26 | 7 | 7 | 35 | 19 | 25 | 31 |
| Others Assetsⓘ | 57 | 60 | 98 | 109 | 108 | 104 | 92 | 121 | 131 | 137 |
| Total Assets ⓘ | 231 | 265 | 351 | 361 | 376 | 398 | 405 | 475 | 512 | 604 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 28 | 68 | 20 | 30 | 32 | 30 | 37 | 40 | 11 | 46 |
| PBT ⓘ | 20 | 22 | 26 | 16 | 43 | 29 | 27 | 47 | 51 | 97 |
| Adjustment ⓘ | 18 | 63 | 2 | 3 | -13 | 7 | -7 | -6 | 1 | -44 |
| Changes in Working Capital ⓘ | -3 | 10 | 3 | 19 | 8 | 9 | 19 | 11 | -26 | 9 |
| Tax Paid ⓘ | -7 | -27 | -11 | -7 | -6 | -15 | -2 | -13 | -16 | -16 |
| Cash Flow From Investing Activity ⓘ | -9 | -38 | -37 | -11 | -19 | -20 | -39 | -40 | -5 | -33 |
| Capex | -9 | -6 | -20 | 1 | 14 | -15 | -1 | -9 | -5 | -11 |
| Net Investments | 0 | -32 | -9 | -6 | -39 | -9 | -40 | -42 | 1 | -33 |
| Others ⓘ | 0 | 0 | -8 | -6 | 7 | 4 | 3 | 11 | -1 | 11 |
| Cash Flow From Financing Activityⓘ | -18 | -18 | 7 | -5 | -17 | -10 | -2 | -2 | -6 | -8 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | -16 | -8 | 0 | 0 | 0 | -1 | -1 | 0 | 0 | 0 |
| Interest Paid ⓘ | -3 | -2 | -1 | 0 | 0 | -1 | 0 | 0 | 0 | 0 |
| Dividend Paid ⓘ | -3 | -6 | -1 | -4 | -4 | -9 | 0 | -3 | -5 | -5 |
| Others ⓘ | 4 | -2 | 8 | 0 | -13 | 0 | 0 | 2 | -1 | -3 |
| Net Cash Flow ⓘ | 1 | 12 | -10 | 14 | -4 | 0 | -4 | -1 | -1 | 4 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 14.96 | 41.8 | 9.98 | 5.33 | 13.44 | 8.85 | 9.48 | 13.46 | 12.24 | 21.72 |
| ROCE (%) | 18.22 | 46.48 | 14.29 | 7.94 | 20.6 | 13.74 | 11.99 | 18.1 | 17.1 | 27.84 |
| Asset Turnover Ratio | 1.35 | 1.35 | 1 | 0.87 | 0.9 | 0.87 | 0.65 | 0.75 | 0.73 | 0.69 |
| PAT to CFO Conversion(x) | 2 | 1.42 | 1.25 | 3 | 1.19 | 1.58 | 1.68 | 1.14 | 0.31 | 0.61 | Working Capital Days |
| Receivable Days | 46 | 42 | 41 | 36 | 27 | 28 | 35 | 25 | 28 | 28 |
| Inventory Days | 52 | 55 | 59 | 55 | 48 | 47 | 55 | 41 | 45 | 45 |
| Payable Days | 160 | 157 | 166 | 181 | 149 | 167 | 165 | 115 | 131 | 133 |
Albert David was incorporated in the year 1938. The company is a part of Kothari group.
Albert David, which has decades of illustrious presence in the health care industry, manufactures pharmaceutical formulations and bulk drugs, infusion solutions and oral solids, disposable syringes and needles and herbal formulations. The company exports these products to Vietnam, Russia, Belarus, Egypt, Bangladesh, Kenya, Tanzania, Uganda, Sudan, Ethiopia, Nigeria, Zaire, Haiti, Brazil, Canada, USA, UK, Netherlands and Germany as the company is a WHO-approved supplier.
It also has DMF for the bulk drugs, Tolbutamide and Chlorpropamide with the US Food and Drugs Administration (USFDA). The manufacturing facility for these products has been inspected and validated by the US drug regulator.
The manufacturing plants of the company are located at Ghaziabad near New Delhi, Kolkata and Mandideep near Bhopal.
The company`s amino acid range under the brand name of Alamin contains pure crystalline amino acid of high international standards manufactured under a unique technology, which conforms to WHO and FAO recommendations. In the herbal segment, the company sells its products under brand names like Adliv, which is a hepato protective and Siotone capsule, which is the only adaptogen indicated for stress.
ADL has tie-ups with Ajinomoto Co and Roussel Morishita Co of Japan for manufacturing and marketing a wide range of crystalline amino acid infusion solutions, oral solids and liquids in India.
Products offered by the Company:
The company is operating in major therapeutic segments that include:
Future Plans:The company will explore the possibilities for export of its IV fluids, small volume parenterals and disposable syringes in addition to its existing range.
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
